NCT05215561Completed
Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP
A Special Drug Use-results Survey to Evaluate the Safety and Efficacy of Subcutaneous Administration of Cosentyx in Pediatric Patients With Psoriasis Vulgaris, Psoriatic Arthritis, or Pustular Psoriasis
Source: ClinicalTrials.gov · Last updated 8 Jun 2025
Brief summary (registry, in English)
This was a multicenter, centrally registered observational study without a control group. This observational study was a specified drug use-results survey conducted under GPSP to collect information on safety and efficacy during the observation period (52 weeks after the start of treatment with this drug) in pediatric patients with psoriasis vulgaris, psoriatic arthritis, or pustular psoriasis who received this drug.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 36 (actual)
- First submitted
- 19 Jan 2022
- Start date
- 14 Feb 2022
- Primary completion date
- 28 Sept 2024
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Psoriasis, Psoriatic arthritis
- NCT number
- NCT05215561
What you commit to
- Study type: Observational
- Participants enrolled: 36
- From 14 Feb 2022 to the primary completion date, 28 Sept 2024
- 20 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with this drug
- Participation in an interventional study (e.g., a clinical trial) at the time of starting this drug.
Who the study is looking for
- Patients who have obtained written consent from their legally acceptable representative to cooperate in this survey before the start of treatment with this drug
- Patients aged less than 18 years at the start of treatment with this drug
- Patients newly treated with this drug for any of the following diseases: Psoriasis vulgaris, psoriatic arthritis, pustular psoriasis
Age in the registry: 0 years to 17 years · Sex: All · Does not accept healthy volunteers
Sites (20)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.